Regeneron's recent purchase of the Quad plant in Saratoga Springs ranks among the biggest local real estate deals of the year ...

Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $1014.59 which represents a decrease of $-25.68 or -2.47% from the prior close of $1040.27. The stock opened at $1037.5 and ...

Currently trading with a volume of 421,493, the REGN's price is down by 0.0%, now at $1040.27. RSI readings suggest the stock ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth ...

Regeneron Pharmaceuticals has purchased Quad’s shuttered printing plant in Saratoga Springs, sparking hopes for economic ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...

Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its ...

The million-square-foot-plus complex was listed for sale earlier this year after its previous owner, Wisconsin-based ...

Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00.